ResMed Q4 Revenue Beats Expectations Despite Margin Pressure

ResMed reported fourth-quarter 2026 revenue of $1.46 billion, representing an 8.6% increase compared to the same period last year. While the company beat adjusted earnings per share estimates, the financial results highlighted significant pressure on operating margins. This margin compression stems from elevated expenditures in research and development alongside higher supply chain costs, a trend that has placed the company’s capital allocation strategy under closer scrutiny.

Despite the positive top-line growth and EPS beat, the stock price declined by 2.3% immediately following the release, with a further 5.1% drop recorded on August 7. The market reaction indicates that investors are prioritizing operational leverage over immediate profitability. The core issue is whether the increased investment in product development and logistics can translate into sustained revenue growth without permanently eroding the company’s net margin profile.

Operational Costs Challenge Margin Stability

The primary risk identified in the latest earnings cycle is the persistence of elevated costs. ResMed is investing heavily in cloud-connected devices and residential care software, which requires substantial R&D outlays. If these expenses do not yield clear operating leverage, earnings growth may lag despite revenue increases. The company’s demand drivers remain intact, but the cost structure is now a critical variable for future performance.

Investors are examining how these costs interact with reimbursement trends and competitive pressures. The business model relies on scaling recurring software fees and device usage. However, if regulatory hurdles or competitor pricing actions intensify, the ability to maintain attractive net margins could be compromised. The current quarter suggests that the balance between investment and return requires careful monitoring.

Consensus Projects Steady Long-Term Growth

According to data from GN markets/earnings, analyst consensus projects ResMed revenue to reach $6.5 billion by 2029. This trajectory assumes an annual revenue growth rate of 5.4%, a modest pace that reflects a steady build rather than a rapid acceleration. Earnings are expected to grow from $1.5 billion to $1.8 billion over the same period, with profit margins remaining relatively stable at approximately 27.5%.

This forecast implies a P/E ratio of 24.3x by 2029, up from the current 18.2x multiple. This valuation premium is justified by the company’s shift toward subscription-like software revenues and the large addressable market for sleep apnea treatments. However, the model assumes that the recent margin squeeze is a temporary adjustment rather than a structural decline in profitability.

GLP-1 Drugs Pose Competitive Threat

An alternative perspective highlights the potential impact of GLP-1 weight loss medications on ResMed’s demand base. Some cautious analysts model only 3.3% annual revenue growth, projecting total revenue of $6.2 billion by 2029. This lower scenario reflects the risk that weight loss treatments may reduce the prevalence of sleep apnea, directly impacting the core device market.

In this bearish case, earnings would reach $1.7 billion by 2029, slightly below the consensus estimate. The divergence between these views underscores the sensitivity of ResMed’s valuation to external medical trends. The company’s ability to mitigate this risk through software diversification and international expansion will be key to maintaining its investment narrative.